Rankings
▼
Calendar
▼
AGMB FY 2024 Earnings Report — AgomAb Therapeutics N.V. American Depositary Shares Revenue & Financial Results | Market Cap Arena
AgomAb Therapeutics N.V. American Depositary Shares
AGMB
FY 2024 Earnings
Reported December 31, 2024
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Metric
FY 2024
Prior Q
FY 2023
QoQ Change
YoY Change
Revenue
$0
—
$0
—
—
Op. Income
-$56M
—
-$36M
—
-54.0%
EPS (Diluted)
$-1.47
—
$-0.36
—
-306.5%
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$46M
Selling & Marketing
$0
General & Administrative
$11M
SG&A Expenses
$11M
Other Expenses
-$1M
Operating Expenses
$56M
Cost & Expenses
$56M
OPERATING INCOME
-$56M
Interest Income
$1M
Interest Expense
$78.3K
Other Income/Expenses
$2M
INCOME BEFORE TAX
-$54M
Income Tax Expense
$4.7K
Net Income from Continuing Ops
-$54M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$54M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$54M
D&A
$363.6K
EBIT
-$54M
EBITDA
-$54M
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
← FY 2023
AGMB Overview
Q4 2024 →